



## Chairman Resignation

**Sydney, NSW, 20 October, 2008** – Giaconda Limited (ASX: GIA), today announced that Mr Richard Woods, Chairman of the board, has resigned for personal reasons. Mr Patrick McLean, Chief Executive Officer of Giaconda, will take on the role of Acting Chairman while a replacement is sought.

Chief Executive Officer, Patrick McLean, stated, “We would like to thank Richard for his assistance and dedication to the Company. We wish him well in his future endeavours.”

**ENDS**

### About Giaconda Limited

Giaconda Limited is a biotechnology company involved in developing and licensing innovative and cost effective medical therapies in the field of gastroenterology. Giaconda's products are targeted towards the treatment of serious conditions that are not adequately addressed by any existing therapy. In this way, Giaconda's products are intended to satisfy these significant unmet medical needs of the gastrointestinal market. The Giaconda portfolio consists of five products, all of which are novel combinations of known compounds. Giaconda has two lead products; Myoconda<sup>®</sup> for the treatment of MAP (*Mycobacterium avium ss paratuberculosis*) infection in Crohn's Disease and Heliconda<sup>®</sup> for the treatment of resistant *Helicobacter pylori* infection.

*Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.*

### CONTACTS:

Giaconda	Media & Investor Relations
Patrick McLean Chief Executive Officer	Fay Weston Director, Talk Biotech
T: +61 (0)2 9370 0069	T: +61 (0)422 206036
pmclean@giacondalimited.com	fayweston@talkbiotech.com.au

GIACONDA LIMITED

Ground Floor, 44 East Street, Five Dock NSW 2046 Phone: [612] 9370 0069 Fax: [612] 9712 1469  
email: info@giacondalimited.com ABN 68 108 088 517 www.giacondalimited.com



GIACONDA LIMITED

Ground Floor, 44 East Street, Five Dock NSW 2046 Phone: [612] 9370 0069 Fax: [612] 9712 1469  
email: [info@giacondalimited.com](mailto:info@giacondalimited.com) ABN 68 108 088 517 [www.giacondalimited.com](http://www.giacondalimited.com)